Dicerna's DCR-PHXC a Breakthrough Therapy for rare kidney disorder - Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)

The FDA has designatedDicerna Pharmaceuticals' (DRNA ) RNAi candidate DCR-PHXC a Breakthrough Therapy for the treatment of a rare inherited kidney disorder called primary hyperoxaluria type 1 (PH1).

PH2 and PH3 may be added in the future.

A Phase 2 study, PHYOX2, in PH1 and PH2 is recruiting patients.

Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.

Source: Seekingalpha.com

Powered by NewsAPI.org

Keywords:

Breakthrough therapy • Rare disease • Kidney • Pharmaceutical drug • NASDAQ • Drňa • Food and Drug Administration • Pharmaceutical drug • Drňa • RNA interference • Breakthrough therapy • Chemotherapy • Rare disease • Kidney • Primary hyperoxaluria • Primary hyperoxaluria • Kepler-86 • Phases of clinical research • Breakthrough therapy • Food and Drug Administration • Marketing •